Document text
Morbidity and Mortality Weekly Report
MMWR / September 10, 2021 / Vol. 70 / No. 36 1255 US Department of Health and Human Services/Centers for Disease Control and PreventionHospitalizations Associated with COVID-19 Among Children and Adolescents —
COVID-NET, 14 States, March 1, 2020–August 14, 2021
Miranda J. Delahoy, PhD1,2; Dawud Ujamaa, MS1,3; Michael Whitaker, MPH1; Alissa O’Halloran, MSPH1; Onika Anglin, MPH1,3; Erin Burns1;
Charisse Cummings, MPH1; Rachel Holstein, MPH1; Anita K. Kambhampati, MPH1; Jennifer Milucky, MSPH1; Kadam Patel, MPH1,3;
Huong Pham, MPH1; Christopher A. Taylor, PhD1; Shua J. Chai, MD4,5: Arthur Reingold, MD4,6; Nisha B. Alden, MPH7; Breanna Kawasaki, MPH7;
James Meek, MPH8; Kimberly Yousey-Hindes, MPH8; Evan J. Anderson, MD9,10,11; Kyle P . Openo, DrPH9,10,11; Kenzie Teno, MPH12;
Andy Weigel, LMSW12; Sue Kim, MPH13; Lauren Leegwater, MPH13; Erica Bye, MPH14; Kathryn Como-Sabetti, MPH14; Susan Ropp, PhD15;
Dominic Rudin16; Alison Muse, MPH17; Nancy Spina, MPH17; Nancy M. Bennett, MD18; Kevin Popham, MPH19; Laurie M. Billing, MPH20;
Eli Shiltz, MPH20; Melissa Sutton, MD21; Ann Thomas, MD21; William Schaffner, MD22; H. Keipp Talbot, MD22; Melanie T. Crossland, MPH23;
Keegan McCaffrey24; Aron J. Hall, DVM1; Alicia M. Fry, MD1; Meredith McMorrow, MD1; Carrie Reed, DSc1; Shikha Garg, MD1,*;
Fiona P . Havers, MD1,*; COVID-NET Surveillance Team
On September 3, 2021 this report was posted as an MMWR
Early Release on the MMWR website (https://www.cdc.gov/mmwr).
Although COVID-19–associated hospitalizations and
deaths have occurred more frequently in adults,† COVID-19
can also lead to severe outcomes in children and adolescents
(1,2). Schools are opening for in-person learning, and many prekindergarten children are returning to early care and educa-tion programs during a time when the number of COVID-19
cases caused by the highly transmissible B.1.617.2 (Delta)
variant of SARS-CoV-2, the virus that causes COVID-19, is increasing.
§ Therefore, it is important to monitor indica-
tors of severe COVID-19 among children and adolescents. This analysis uses Coronavirus Disease 2019–Associated Hospitalization Surveillance Network (COVID-NET)
¶ data
to describe COVID-19–associated hospitalizations among U.S. children and adolescents aged 0–17 years. During March 1, 2020–August 14, 2021, the cumulative incidence of COVID-19–associated hospitalizations was 49.7 per 100,000 children and adolescents. The weekly COVID-19–associated hospitalization rate per 100,000 children and adolescents dur-ing the week ending August 14, 2021 (1.4) was nearly five times the rate during the week ending June 26, 2021 (0.3); among children aged 0–4 years, the weekly hospitalization rate during the week ending August 14, 2021, was nearly 10 times that during the week ending June 26, 2021.** During June 20–July 31, 2021, the hospitalization rate among unvaccinated adolescents (aged 12–17 years) was 10.1 times higher than that among fully vaccinated adolescents. Among all hospitalized children and adolescents with COVID-19, the proportions
* These authors contributed equally to this report.
† https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-
discovery/hospitalization-death-by-age.html
§ https://www.cdc.gov/coronavirus/2019-ncov/variants/index.html
¶ https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-
methods.html
** COVID-NET hospitalization data are preliminary and subject to change as
more data become available. In particular, case counts and rates for recent
hospital admissions are subject to lag.with indicators of severe disease (such as intensive care unit
[ICU] admission) after the Delta variant became predominant (June 20–July 31, 2021) were similar to those earlier in the pandemic (March 1, 2020–June 19, 2021). Implementation of preventive measures to reduce transmission and severe out-comes in children is critical, including vaccination of eligible persons, universal mask wearing in schools, recommended mask wearing by persons aged ≥2 years in other indoor public spaces and child care centers,
†† and quarantining as recom-
mended after exposure to persons with COVID-19.§§
COVID-NET conducts population-based surveillance for
laboratory-confirmed COVID-19–associated hospitaliza-tions in 99 counties across 14 states
¶¶ (1). Residents of the
surveillance catchment area who received positive molecular or rapid antigen detection test results for SARS-CoV-2 dur-ing hospitalization or within 14 days before admission were classified as having COVID-19–associated hospitalizations. Unadjusted age-specific cumulative and weekly COVID-19–associated hospitalization rates (hospitalizations per 100,000 children and adolescents residing in the catchment area) during March 1, 2020–August 14, 2021, were calculated by divid-ing the total number of hospitalized patients by the National Center for Health Statistics’ population estimates within each age group for the counties included in the surveillance catch-ment area.*** Among adolescents, who are currently eligible for vaccination
††† (3), age-specific hospitalization rates dur-
ing June 20–July 31, 2021, were calculated by COVID-19
†† https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/about-
face-coverings.html
§§ https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-
isolation.html
¶¶ California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan,
Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.
The included counties have been listed previously. https://www.cdc.gov/mmwr/volumes/69/wr/mm6932e3.htm
*** Rates are calculated using the National Center for Health Statistics’ vintage
2019 bridged-race postcensal population estimates for the counties included in surveillance (https://www.cdc.gov/nchs/nvss/bridged_race.htm).
††† https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/
adolescents.html
090177e198c5caea\Final\Final On: 03-Dec-2021 22:30 (GMT)
FDA-CBER-2022-5812-0071293
Morbidity and Mortality Weekly Report
1256 MMWR / September 10, 2021 / Vol. 70 / No. 36 US Department of Health and Human Services/Centers for Disease Control and Pre ventionvaccination status, which was determined for both hospitalized
patients and the catchment area population using state immu-nization information systems data.
§§§ Because the number of
fully vaccinated persons in the underlying population changed weekly, incidence (cases per 100,000 person-weeks) was cal-culated by dividing the total number of vaccinated hospital-ized adolescents by the sum of vaccinated adolescents in the underlying population each week; the same method was used to calculate incidence among unvaccinated adolescents.
¶¶¶
Rate ratios and 95% confidence intervals (CIs) were calcu-lated. T rained surveillance staff members conducted medical chart abstractions for all pediatric COVID-NET patients using a standardized case report form. Data on the following measures of severe disease were collected: median hospital length of stay, ICU admission, highest level of respiratory support received (i.e., invasive mechanical ventilation [IMV], bilevel positive airway pressure or continuous positive airway pressure, or high-flow nasal cannula), vasopressor use, and in-hospital death. Deaths occurring after hospital discharge were not included in this analysis. To assess COVID-19 severity among hospitalized children and adolescents in the setting of widespread Delta variant circulation, the proportions with measures of severe disease were compared between the periods before (March 1, 2020–June 19, 2021) and after (June 20–July 31, 2021) the Delta variant became the predominant strain circulating in the United States**** ( 4). A Wilcoxon rank sum
test was used to compare medians; chi square or Fisher’s exact tests were used to compare proportions. Data were analyzed using SAS (version 9.4; SAS Institute); statistical significance
§§§ The Food and Drug Administration granted emergency use authorization
for the Pfizer-BioNTech COVID-19 vaccine for adolescents aged
12–15 years on May 10, 2021. The earliest date that adolescents in this age group could have met the definition for being a fully vaccinated patient hospitalized with COVID-19 was June 14, 2021. Because vaccination data are subject to lag, rates by vaccination status were only calculated through July 31, 2021.
¶¶¶ Fully vaccinated adolescents with COVID-19–associated hospitalizations
were defined as those who had received a second vaccine dose ≥14 days before a positive SARS-CoV-2 test result associated with their hospitalization. Adolescents whose positive SARS-CoV-2 test date was ≥14 days after a single dose through <14 days after a second dose were considered partially vaccinated and were not included in rates; adolescents who had received a single dose of vaccine <14 days before the positive SARS-CoV-2 test result were also not included in rates If the SARS-CoV-2 test date was not available, hospital admission date was used. Adolescents whose vaccination status had not yet been verified using the immunization information system data were considered to having missing vaccination status and were excluded. Adolescents whose vaccination status was checked against the immunization information system and who did not have documented receipt of any vaccine dose before the test date were considered unvaccinated. Additional COVID-NET methods for determining vaccination status have been described previously. https://medrxiv.org/cgi/content/short/2021.08.27.21262356v1
**** https://covid.cdc.gov/covid-data-tracker/#variant-proportionswas defined as p<0.05. This activity was reviewed by CDC
and was conducted consistent with applicable federal law and CDC policy.
††††
During March 1, 2020–August 14, 2021, COVID-NET
identified 49.7 cumulative COVID-19–associated hospital-izations per 100,000 children and adolescents (Figure 1); rates were highest among children aged 0–4 years (69.2) and adolescents aged 12–17 years (63.7) and lowest among children aged 5–11 years (24.0). Weekly hospitalization rates were at their lowest in 2021 during the weeks ending June 12–July 3 (0.3 per 100,000 children and adolescents each week) (Figure 2). During a subsequent 6-week period after the Delta variant became predominant, rates rose each week to 1.4 during the week ending August 14, 2021, which was 4.7 times the rate during the week ending June 26, 2021 and approached the peak hospitalization rate of 1.5 observed during the week ending January 9, 2021.
§§§§ Weekly rates increased among
all age groups; the sharpest increase occurred among children aged 0–4 years, for whom the rate during the week ending August 14, 2021 (1.9) was nearly 10 times that during the week ending June 26, 2021 (0.2). During June 20–July 31, 2021, among 68 adolescents hospitalized with COVID-19 whose vaccination status had been ascertained, 59 were unvaccinated, five were partially vaccinated, and four were fully vaccinated; the hospitalization rate among unvaccinated adolescents was 0.8 per 100,000 person-weeks (95% CI = 0.6–0.9), compared with 0.1 (95% CI = 0.0–0.1) in fully vaccinated adolescents (rate ratio = 10.1; 95% CI = 3.7–27.9).
Among 3,116 hospitalized children and adolescents with
COVID-19 during March 1, 2020–June 19, 2021, for whom complete clinical data were available,
¶¶¶¶ 827 (26.5%) were
admitted to an ICU, 190 (6.1%) required IMV, and 21 (0.7%) died. Among 164 hospitalized children and adolescents with COVID-19 during June 20–July 31, 2021, for whom complete clinical data were available,***** 38 (23.2%) were admitted to
†††† 45 C.F .R. part 46.102(l)(2); 21 C.F .R. part 56; 42 U.S.C. Sect. 241(d);
5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.
§§§§ Smoothed 3-week running averages are used for visualization purposes in
Figure 2; however, raw (nonaveraged) age-specific weekly rates are used
in the text of the report. The smoothed 3-w
eek running average rate of
COVID-19–associated hospitalizations during the week ending January 9, 2021 (displayed in Figure 2) is 1.3 hospitalizations per 100,000
children and adolescents.
¶¶¶¶ Among the 3,194 children and adolescents with COVID-19–associated
hospitalizations during March 1, 2020–June 19, 2021, a total of 3,116 (97.6%) had data available on hospital length of stay, ICU admission, receipt of IMV or other respiratory support, vasopressor use, and in-hospital death at the time of reporting.
***** Among the 191 children and adolescents with COVID-19–associated
hospitalizations during June 20, 2020–July 31, 2021, a total of 164 (85.9%) had data available on hospital length of stay, ICU admission, receipt of IMV or other respiratory support, vasopressor use, and in-hospital death at the time of reporting.
090177e198c5caea\Final\Final On: 03-Dec-2021 22:30 (GMT)
FDA-CBER-2022-5812-0071294
Morbidity and Mortality Weekly Report
MMWR / September 10, 2021 / Vol. 70 / No. 36 1257 US Department of Health and Human Services/Centers for Disease Control and PreventionFIGURE 1. COVID-19–associated cumulative hospitalizations per 100,000 children and adolescents,* by age group — COVID-NET, 14 s tates,†
March 1, 2020–August 14, 2021
01020304050607080
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
2020 2021Hospitalizations per
100,000 children and adolescents
Surveillance week end date72 141 82 1 3 2 7 1 1 2 582 2 519 3 17 31 14 28 12 26 9 23 6 20 6 20 3 17 11 5 2 9 1 2 26 10 71 4 24 30 16Overall 0–17 yrs
12–17 yrs5–11 yrs0–4 yrs
* Rates are subject to change as additional data are reported.
† Select counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.
an ICU, 16 (9.8%) required IMV, and three (1.8%) died. The
differences in these indicators of severe disease between the two periods were not statistically significant (Table).
Discussion
Weekly COVID-19–associated hospitalization rates rose
rapidly during late June to mid-August 2021 among U.S. children and adolescents aged 0–17 years; by mid-August, the rate among children aged 0–4 years was nearly 10 times the rate 7 weeks earlier. This increase coincides with wide-spread circulation of the highly transmissible Delta variant. COVID-NET data indicate that vaccination was highly effective in preventing COVID-19–associated hospitaliza-tions in adolescents during late June to late July 2021. Since March 2020, approximately one in four hospitalized children and adolescents with COVID-19 has required intensive care, although the proportions with indicators of severe disease during the period when the Delta variant predominated were generally similar compared with those earlier in the pandemic. The observed indicators of severe COVID-19 among children and adolescents, as well as the potential for serious longer-term sequelae (e.g., multisystem inflammatory syndrome in chil-dren) documented elsewhere ( 5,6), underscore the importance of implementing multipronged preventive measures to reduce severe COVID-19 disease, including nonpharmaceutical interventions and vaccination among eligible age groups.
†††††
Among adolescents aged 12–17 years, the only pediatric age
group for whom a COVID-19 vaccine is currently approved, hospitalization rates were approximately 10 times higher in unvaccinated compared with fully vaccinated adolescents, indicating that vaccines were highly effective at preventing serious COVID-19 illness in this age group during a period when the Delta variant predominated. As of July 31, 2021, 32% of U.S. adolescents had completed a COVID-19 vac-cination series ( 7); increasing vaccination coverage among
adolescents, as well as expanding eligibility for COVID-19 vaccination to younger age groups if approved and recom-mended, is expected to reduce severe COVID-19–associated outcomes among children and adolescents.
Similar to another recent analysis, COVID-NET data
suggest that indicators of severe disease among hospitalized children during an early period when the Delta variant predom-inated were generally similar to those observed earlier in the pandemic (8). T rends in outcomes will need to be monitored closely as more data become available. For example, whereas
††††† https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html
090177e198c5caea\Final\Final On: 03-Dec-2021 22:30 (GMT)
FDA-CBER-2022-5812-0071295
Morbidity and Mortality Weekly Report
1258 MMWR / September 10, 2021 / Vol. 70 / No. 36 US Department of Health and Human Services/Centers for Disease Control and Pre ventionFIGURE 2. COVID-19–associated weekly hospitalizations per 100,000 children and adolescents,* by age group — COVID-NET, 14 state s,†
March 1, 2020–August 14, 2021 (3-week smoothed running averages)§Hospitalizations per
100,000 children and adolescents
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug
2020 2021
Surveillance week end date72 141 82 1 3 2 7 1 1 2 582 2 519 3 17 31 14 28 12 26 9 23 6 20 6 20 3 17 11 5 2 9 1 2 26 10 71 4 24 30 160.00.51.01.52.02.5Overall 0–17 yrs
12–17 yrs5–11 yrs0–4 yrs
* Rates are subject to change as additional data are reported.
† Select counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, New York, Ohio , Oregon,
Tennessee, and Utah.
§ Smoothed running averages are used for visualization purposes only.
the point estimate of the proportion of hospitalized children
who required IMV during the period of Delta predominance (9.8%) was higher than that earlier in the pandemic (6.1%), the comparison of these proportions was based on a relatively small number of children (16) requiring IMV during the period of Delta predominance, and the difference was not statistically significant (p = 0.06). Further, surveillance data limited to hospitalized persons cannot be used to assess whether increases in COVID-19–associated hospitalization rates among children and adolescents are due to increased community SARS-CoV-2 transmission or increased disease severity caused by the Delta variant.
The findings in this report are subject to at least five limita-
tions. First, children and adolescents meeting COVID-NET criteria with a positive SARS-CoV-2 test result might have been hospitalized primarily for reasons other than COVID-19 (2), resulting in potential overestimations of hospitalization rates. Second, COVID-19–associated hospitalizations might have been missed because of testing practices and test avail-ability. Third, the number of hospitalized children with severe outcomes was small during June 20–July 31, 2021, limiting comparisons between periods before and during Delta variant predominance. Fourth, the number of fully vaccinated hospi-talized adolescents remained low at the time of reporting, and hospitalization rates stratified by vaccination status are subject to error if misclassification of vaccination status occurred. Finally, the COVID-NET catchment areas include approxi-mately 10% of the U.S. population; thus, findings might not be nationally generalizable.
Rates of COVID-19–associated hospitalization among
children and adolescents increased rapidly from late June to mid-August 2021, coinciding with predominance of the Delta variant. With more activities resuming, including in-person school attendance and a return of younger children to congregate child care settings, preventive measures to reduce the incidence of severe COVID-19 are critical. Universal indoor masking is rec-ommended for all teachers, staff members, students, and visitors in kindergarten through grade 12 schools, regardless of vaccina-
tion status.
§§§§§ CDC recommends that persons aged ≥2 years
who are unvaccinated, as well as vaccinated persons in areas of substantial or high transmission, wear masks in all indoor public
spaces.
¶¶¶¶¶ CDC also recommends that child care centers serv-
ing children too young to be vaccinated consider implementing
§§§§§ https://www.cdc.gov/coronavirus/2019-ncov/community/schools-
childcare/k-12-guidance.html
¶¶¶¶¶ https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.
html
090177e198c5caea\Final\Final On: 03-Dec-2021 22:30 (GMT)
FDA-CBER-2022-5812-0071296
Morbidity and Mortality Weekly Report
MMWR / September 10, 2021 / Vol. 70 / No. 36 1259 US Department of Health and Human Services/Centers for Disease Control and PreventionTABLE. Clinical interventions and outcomes among children and
adolescents aged 0-17 years during COVID-19–associated hospitalizations — COVID-NET, 14 states,* March 1, 2020– June 19, 2021
and June 20–July 31, 2021
Interventions and
outcomesChildren and adolescents hospitalized,
No. (%)
p-value§March 1, 2020–
June 19, 2021
(N = 3,116)†June 20–
July 31, 2021
(N = 164)†
Hospital length of
stay, median (interquartile range)3 (2–5) 2 (1–4) 0.01
Outcome
Died during
hospitalization21 (0.7) 3 (1.8) 0.12
ICU admission 827 (26.5) 38 (23.2) 0.34
Vasopressor
support233 (7.5) 13 (7.9) 0.83
Highest level of respiratory support
¶
High flow nasal
cannula 162 (5.2) 13 (7.9) 0.13
BiPAP/CPAP 131 (4.2) 6 (3.7) 0.73
Invasive mechanical
ventilation 190 (6.1) 16 (9.8) 0.06
Abbreviations: BiPAP = bilevel positive airway pressure; CPAP = continuous
positive airway pressure; ICU = intensive care unit. * Select counties in California, Colorado, Connecticut, Georgia, Iowa, Maryland,
Michigan, Minnesota, New Mexico, New York, Ohio, Oregon, Tennessee, and Utah.
† Includes those with complete clinical data on hospital length of stay, ICU
admission, highest level of respiratory support (invasive mechanical ventilation, BiPAP/CPAP , or high flow nasal cannula), vasopressor support, and disposition discharge (i.e., discharged alive or died in-hospital).
§ Medians were compared using a Wilcoxon rank sum test. Proportions were
compared using chi square tests. The proportions who died during hospitalization were compared using Fisher’s exact test.
¶ Highest level of respiratory support for each patient that needed respiratory support.
universal indoor masking for persons aged ≥2 years.****** All
persons who are eligible should receiv
e COVID-19 vaccines to
reduce the risk for severe disease for themselves and others with
whom they come into contact, including children who are cur-rently too young to be vaccinated.
Acknowledgments
Brooke Heidenga, Joelle Nadle, Susan Brooks, Alison Ryan,
California Emerging Infections Program; Tessa Carter, Paula
Clogher, Maria Correa, Daewi Kim, Carol Lyons, Amber Maslar, Adam Misiorski, Connecticut Emerging Infections Program, Yale School of Public Health; Jeremiah Williams, Siyeh Gretzinger, Jana Manning, Asmith Joseph, Allison Roebling, Chandler Surell, Stephanie Lehman, Taylor Eisenstein, Gracie Chambers, Grayson Kallas, Annabel Patterson, Georgia Emerging Infections Program, Georgia Department of Health; Foundation for Atlanta Veterans Education and Research, Atlanta Veterans Affairs Medical Center; Maya L. Monroe, Patricia A. Ryan, Alicia Brooks, Elisabeth Vaeth, ****** https://www.cdc.gov/coronavirus/2019-ncov/community/schools-
childcare/child-care-guidance.htmlSummary
What is already known about this topic?
COVID-19 can cause severe illness in children and adolescents.
What is added by this report?
Weekly COVID-19–associated hospitalization rates among
children and adolescents rose nearly five-fold during late June–mid-August 2021, coinciding with increased circulation of the highly transmissible SARS-CoV-2 Delta variant. The propor-tions of hospitalized children and adolescents with severe disease were similar before and during the period of Delta predominance. Hospitalization rates were 10 times higher among unvaccinated than among fully vaccinated adolescents.
What are the implications for public health practice?
Preventive measures to reduce transmission and severe
outcomes in children and adolescents are critical, including vaccination, universal masking in schools, and masking by persons aged ≥2 years in other indoor public spaces and child care centers.
Cindy Zerrlaut, David Blythe, Maryland Department of Health;
Rachel Park, Michelle Wilson, Maryland Emerging Infections Program — The Johns Hopkins Bloomberg School of Public Health; Jim Collins, Shannon Johnson, Justin Henderson, Libby Reeg, Alexander Kohrman, Val Tellez Nunez, Sierra Peguies-Khan, Chloe Brown, Michigan Department of Health and Human Services; Austin Bell, Kayla Bilski, Emma Contestabile, Claire Henrichsen, Amanda Gordon, Cynthia Kenyon, Melissa McMahon, Katherine Schleiss, Samantha Siebman, Emily Holodnick, Lisa Nguyen, Kristen Ehresmann, Minnesota Department of Health; Emily B. Hancock, Yadira Salazar-Sanchez, Nancy Eisenberg, Melissa Christian, Mayvilynne Poblete, Wickliffe Omondi, New Mexico Emerging Infections Program; Suzanne McGuire, Katarina Manzi, Grant Barney, New York State Department of Health; Virginia Cafferky, Christine Long, RaeAnne Kurtz, Maria Gaitan, University of Rochester School of Medicine and Dentistry; Nicholas Fisher, Krista Lung, Maya Sculllin, Ohio Department of Health; Ama Owusu-Dommey, Breanna McArdle, Emily Youngers, Sam Hawkins, Public Health Division, Oregon Health Authority; Kylie Seeley, Oregon Health & Science University School of Medicine; Katie Dyer, Karen Leib, Terri McMinn, Danielle Ndi, John Ujwok, Gail Hughett, Emmanuel Sackey, Kathy Billings, Anise Elie, Manideepthi Pemmaraju, Vanderbilt University Medical Center; Amanda Carter, Andrea Price, Andrew Haraghey, Ashley Swain, Caitlin Shaw, Ian Buchta, Jake Ortega, Laine McCullough, Ryan Chatelain, Tyler Riedesel, Salt Lake County Health Department; Alvin Shultz, Robert W. Pinner, Rainy Henry, Sonja Mali Nti-Berko, Susan Gantt, CDC; Mimi Huynh, Council of State and Territorial Epidemiologists.
COVID-NET Surveillance Team
Pam Daily Kirley, California Emerging Infections Program; Sarah
McLafferty, Colorado Department of Public Health & Environment; Isaac Armistead, Colorado Department of Public Health &
090177e198c5caea\Final\Final On: 03-Dec-2021 22:30 (GMT)
FDA-CBER-2022-5812-0071297
Morbidity and Mortality Weekly Report
1260 MMWR / September 10, 2021 / Vol. 70 / No. 36 US Department of Health and Human Services/Centers for Disease Control and Pre ventionEnvironment; Emily Fawcett, Georgia Emerging Infections Program,
Georgia Department of Health and Foundation for Atlanta Veterans Education and Research, Decatur, Georgia, and Atlanta Veterans Affairs Medical Center, Atlanta, Georgia; Katelyn Ward, Georgia Emerging Infections Program, Georgia Department of Health, and Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia; Ruth Lynfield, Minnesota Department of Health; Richard Danila, Minnesota Department of Health; Sarah Khanlian, New Mexico Emerging Infections Program; Kathy Angeles, New Mexico Emerging Infections Program; Kerianne Engesser, New York State Department of Health; Adam Rowe, New York State Department of Health; Christina Felsen, University of Rochester School of Medicine and Dentistry, Rochester, New York; Sophrena Bushey, University of Rochester School of Medicine and Dentistry, Rochester, New York; Nasreen Abdullah, Public Health Division, Oregon Health Authority; Nicole West, Public Health Division, Oregon Health Authority; Tiffanie Markus, Vanderbilt University Medical Center, Nashville, Tennessee; Mary Hill, Salt Lake County Health Department, Salt Lake City, Utah; Andrea George, Salt Lake County Health Department, Salt Lake City, Utah.
Corresponding author: Miranda J. Delahoy; [email protected].
1CDC COVID-19 Response Team; 2Epidemic Intelligence Service, CDC;
3General Dynamics Information Technology, Atlanta, Georgia; 4California
Emerging Infections Program, Oakland, California; 5Career Epidemiology
Field Officer Program, CDC; 6University of California, Berkeley School of
Public Health, Berkeley, California; 7Colorado Department of Public Health
and Environment; 8Connecticut Emerging Infections Program, Yale School of
Public Health, New Haven, Connecticut; 9Emory University School of
Medicine, Atlanta, Georgia; 10Georgia Emerging Infections Program, Georgia
Department of Health; 11Atlanta Veterans Affairs Medical Center, Atlanta,
Georgia; 12Iowa Department of Health; 13Michigan Department of Health
and Human Services; 14Minnesota Department of Health; 15New Mexico
Emerging Infections Program, New Mexico Department of Health, Santa Fe,
New Mexico; 16New Mexico Emerging Infections Program, University of New
Mexico, Albuquerque, New Mexico; 17New York State Department of Health;
18University of Rochester School of Medicine and Dentistry, Rochester, New
York; 19Rochester Emerging Infections Program, University of Rochester
Medical Center, Rochester, New York; 20Ohio Department of Health; 21Public
Health Division, Oregon Health Authority; 22Vanderbilt University Medical
Center, Nashville, Tennessee; 23Salt Lake County Health Department, Salt
Lake City, Utah; 24Utah Department of Health.
All authors have completed and submitted the International
Committee of Medical Journal Editors form for disclosure of
potential conflicts of interest. William Schaffner reports consultant fees from VBI Vaccines, outside the submitted work. Eli Shiltz and Laurie M. Billing report grant funding from the Council of State and Territorial Epidemiologists (CSTE) for the population-based Influenza Hospitalization Surveillance Project (IHSP) and COVID-NET activities. Lauren Leegwater and Sue Kim report grant support from CSTE through the Michigan Department of Health and Human Services. Andy Weigel and Kenzie Teno report grant support from CSTE for data collection and participation in ongoing meetings related to COVID-19 hospitalization surveillance. Evan J. Anderson reports grants for clinical trials from Pfizer, Merck, PaxVax, Micron, Sanofi-Pasteur, Janssen, MedImmune, and GSK; consulting fees from Sanofi-Pasteur, Pfizer, Janssen, and Medscape; personal fees for data safety monitoring board participation from Kentucky Bioprocessing, Inc. and Sanofi-Pasteur; and institutional funding from the National Institutes of Health to conduct clinical trials of Moderna and Janssen COVID-19 vaccines. No other potential conflicts of interest were disclosed.
References
1. Kim L, Whitaker M, O’Halloran A, et al.; COVID-NET Surveillance
Team. Hospitalization rates and characteristics of ch ldren aged <18 years
hospitalized with laboratory-confirmed COVID-19—COVID-NET, 14 states, March 1–July 25, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1081–8. PMID:32790664 https://doi.org/10.15585/mmwr.mm6932e3
2. Havers FP , Whitaker M, Self JL, et al.; COVID-NET Surveillance Team.
Hospitalization of adolescents aged 12–17 years with laboratory-confirmed COVID-19—COVID-NET, 14 states, March 1, 2020–April 24, 2021. MMWR Morb Mortal Wkly Rep 2021;70:851–7. PMID:34111061 https://doi.org/10.15585/mmwr.mm7023e1
3. Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee
on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years—United States, May 2021. MMWR Morb Mortal Wkly Rep 2021;70:749–52. PMID:34014913 https://doi.org/10.15585/mmwr.mm7020e1
4. Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech
and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant—National Healthcare Safety Network, March 1–August 1, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1163–6. PMID:34437519 https://doi.org/10.15585/mmwr.mm7034e3
5. Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long
COVID in children. Acta Paediatr 2021;110:2208–11. PMID:33835507 https://doi.org/10.1111/apa.15870
6. Feldstein LR, Rose EB, Horwitz SM, et al.; Overcoming COVID-19
Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020;383:334–46. PMID:32598831 https://doi.org/10.1056/
NEJMoa2021680
7. Murthy BP , Zell E, Saelee R, et al. COVID-19 vaccination coverage among
adolescents aged 12–17 years—United States, December 14, 2020–July 31, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1206–13.
8. Siegel DA, Reses HE, Cool AJ, et al. T rends in COVID-19 cases,
emergency department visits, and hospital admissions among children and adolescents aged 0–17 years—United States, August 2020–August 2021. MMWR Morb Mortal Wkly Rep 2021. Epub September 3, 2021.
090177e198c5caea\Final\Final On: 03-Dec-2021 22:30 (GMT)
FDA-CBER-2022-5812-0071298